Derek J.  Maetzold net worth and biography

Derek Maetzold Biography and Net Worth

Insider of Castle Biosciences
Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis).  Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.

What is Derek J. Maetzold's net worth?

The estimated net worth of Derek J. Maetzold is at least $1.49 million as of March 20th, 2024. Mr. Maetzold owns 69,806 shares of Castle Biosciences stock worth more than $1,485,472 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Maetzold may own. Additionally, Mr. Maetzold receives a salary of $1,450,000.00 as Insider at Castle Biosciences. Learn More about Derek J. Maetzold's net worth.

How old is Derek J. Maetzold?

Mr. Maetzold is currently 62 years old. There are 4 older executives and no younger executives at Castle Biosciences. Learn More on Derek J. Maetzold's age.

What is Derek J. Maetzold's salary?

As the Insider of Castle Biosciences, Inc., Mr. Maetzold earns $1,450,000.00 per year. Learn More on Derek J. Maetzold's salary.

How do I contact Derek J. Maetzold?

The corporate mailing address for Mr. Maetzold and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected]. Learn More on Derek J. Maetzold's contact information.

Has Derek J. Maetzold been buying or selling shares of Castle Biosciences?

Derek J. Maetzold has not been actively trading shares of Castle Biosciences within the last three months. Learn More on Derek J. Maetzold's trading history.

Who are Castle Biosciences' active insiders?

Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.

Are insiders buying or selling shares of Castle Biosciences?

During the last year, Castle Biosciences insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $69,024.00. During the last year, insiders at the sold shares 40 times. They sold a total of 247,483 shares worth more than $5,133,815.82. The most recent insider tranaction occured on March, 20th when insider Derek J Maetzold sold 2,295 shares worth more than $46,519.65. Insiders at Castle Biosciences own 7.7% of the company. Learn More about insider trades at Castle Biosciences.

Information on this page was last updated on 3/20/2024.

Derek J. Maetzold Insider Trading History at Castle Biosciences

See Full Table

Derek J. Maetzold Buying and Selling Activity at Castle Biosciences

This chart shows Derek J. Maetzold's buying and selling at Castle Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Castle Biosciences Company Overview

Castle Biosciences logo
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $22.27
Low: $21.33
High: $22.48

50 Day Range

MA: $22.01
Low: $18.06
High: $25.30

2 Week Range

Now: $22.27
Low: $9.26
High: $26.70

Volume

50,341 shs

Average Volume

253,821 shs

Market Capitalization

$611.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9